Treace Medical Conceptsの空売り状況は、投資家がTreace Medical Conceptsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Treace Medical Concepts (NASDAQ:TMCI) 株価情報, 空売り情報

Treace Medical Concepts

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts Inc

<p>Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) today confirmed that the Office of the Comptroller of the Currency's 2015 agreements relating to the company's previously held financial subsidiaries have terminated. This is the thirteenth consent order closed by Wells Fargo's regulators since 2019 and the seventh since the beginning of the year. The company's one remaining consent order is the 2018 consent order with the Federal Reserve Board.</p>


News

Wells Fargo Confirms Termination Of OCC's 2015 Agreements On Financial Subsidiaries

<p><a href="https://www.bloomberg.com/news/articles/2025-05-29/williams-files-petition-to-revive-new-york-gas-pipeline-project?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-29/williams-files-petition-to-revive-new-york-gas-pipeline-project?embedded-checkout=true</a></p>


General

'Williams Files Petition to Revive New York Gas Pipeline Project'- Bloomberg

WIIM

Hershey shares are trading higher amid a pullback in cocoa prices.

<p>Israeli multinational pharmaceutical company <strong>Teva Pharmaceutical Industries Ltd</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) hosted 2025 Innovation &amp; Strategy Day on Thursday to launch the acceleration phase of its &#8220;Pivot to Growth&#8221; strategy and to discuss portfolio priorities.</p>
<p>The company outlined its plan to evolve into a leading biopharmaceutical company, emphasizing its innovative medicines franchise and a strong generics and biosimilars portfolio.</p>
<p>President and CEO <strong>Richard Francis</strong> said the company is entering a new chapter focused on scaling its innovative medicines franchise while maintaining strength in generics and biosimilars.</p>
<p>Francis highlighted that Teva has completed Phase 1 of its "Pivot to Growth" plan, achieving nine consecutive <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45666576/teva-reaffirms-pivot-to-growth-strategy-progress-with-launch-of-acceleration-phase-at-2025-innovat" rel="noreferrer noopener">quarters of growth</a>.</p>
<p><strong><em>Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum</a></em></strong></p>
<p>The company's innovative medicines portfolio, including Austedo, Ajovy, and Uzedy, generated over $2.3 billion in 2024 revenue.</p>
<p>Teva's generics business has also rebounded, with a 5% increase in revenue across regions and a top-three global portfolio that may yield five new product launches by 2027.</p>
<p>&#8220;The past two years have been about returning to growth&#8230;Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio,&#8221; Francis said.</p>
<p>Teva aims to build a $5 billion innovative medicines franchise by 2030, led by its key assets and a strong late-stage pipeline.</p>
<p>Austedo is expected to surpass $2.5 billion in sales by 2027 and reach over $3 billion by 2030. Ajovy is in 43 countries, with additional launches expected this year. Uzedy has rapidly captured over 60% of the risperidone long-acting injectable (LAI) market, and the upcoming olanzapine LAI is expected to expand Teva's footprint in schizophrenia treatment.</p>
<p>The late-stage pipeline includes promising assets such as duvakitug for inflammatory bowel disease, DARI for asthma, and emrusolmin for Multiple System Atrophy, each carrying multibillion-dollar peak sales potential.</p>
<p>TEV-‘408, an anti-IL-15 antibody for celiac disease, has received FDA fast-track status and could exceed $1 billion in peak sales.</p>
<p>Teva's generics, biosimilars, and over-the-counter (OTC) segments remain critical revenue drivers.</p>
<p>The company has 13 biosimilars in development, with five launches planned by 2027. Its $1.1 billion OTC business continues to outperform the market with double-digit growth, while ongoing manufacturing transformations aim to improve competitiveness and margins.</p>
<p>Teva reaffirmed its 2027 financial targets, including a 30% operating margin, more than $2.7 billion in free cash flow, and over $700 million in savings from operational efficiencies.</p>
<p><strong>Price Action:</strong> TEVA stock is trading lower by 3.55% to $17.55 at last check Thursday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/news/earnings/25/05/45670275/build-a-bear-sticks-to-outlook-despite-tariff-pressure-stock-soars-25" target="_blank" rel="noreferrer noopener"><em>Build-A-Bear Sticks To Outlook Despite Tariff Pressure, Stock Soars 25%</em></a></strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Biotech

Large Cap

Health Care

Movers

TEVA

Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030

Rumors

Trading Ideas

GILD

Watching Gilead Sciences; Hearing Investor Business Daily's SwingTrader Buys Stock

<p><i>New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time</i></p>
<p>SAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4438250-1&amp;h=2291622851&amp;u=https%3A%2F%2Fwww.science.org%2Fdoi%2F10.1126%2Fscience.ads7373&amp;a=published+today">published today</a> in <i>Science</i> illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases. By turning data into insights, this technology is expected to help researchers accelerate new breakthroughs in diagnosis for rare diseases.</p>
<p>Currently, only about 30% of rare disease patients receive an accurate diagnosis from exome sequencing. For many patients, insights may be hidden in what are known as "noncoding regions," which comprise over 98% of the genome and may hold the key to increasing the diagnostic rate.</p>
<p>PromoterAI will be accessible through Illumina Connected Software and it is available today as part of DRAGEN&#x2122; secondary analysis. Precomputed PromoterAI scores for all human promoter single-nucleotide variants are freely available for academic and noncommercial research use. Illumina Connected Software supports seamless integration with next-generation sequencing and array workflows for genomics and multiomics. Researchers, bioinformaticians, and clinical geneticists can use Illumina Connected Software to prioritize variants that are important to a case, gain critical insights, and accelerate their precision medicine dry lab operations.</p>


ILMN

Illumina Unveils PromoterAI, New AI Algorithm That Accurately Deciphers Pathogenic Regulatory Genetic Variants In Noncoding Regions Of Human Genome

<p><a href="https://www.youtube.com/watch?v=mif6Rc5VBEY">https://www.youtube.com/watch?v=mif6Rc5VBEY</a></p>


Politics

Economics

Federal Reserve

Fed's Kulger Says Need To Better Understand U.s. Assets' Safe Haven Status; Says 'Keenly Interested' In Connections Between Economy And Commercial Real Estate

Fed's Kulger Does Not Comment On Economic, Monetary Policy Outlook In Opening Remarks To Fed Macro-finance Workshop In Washington; Says Watching To Better Understand Link Between Trade And Market Vulnerability; Says Monitoring Shifts In Possible Lower Demand For U.S. Assets

ROIV

Roivant Sciences shares are trading higher following Q4 reported financial results.

IMVT

Immunovant shares are trading higher following a Q4 EPS beat.

<p>Analysts' ratings for Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.25, a high estimate of $20.00, and a low estimate of $15.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 17.86%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748541719_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Superior Gr of Cos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Kupinski</td>
<td>Noble Capital Markets</td>
<td>Announces</td>
<td>Outperform</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Steinke</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kevin Steinke</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Superior Gr of Cos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Superior Gr of Cos compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Superior Gr of Cos's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Superior Gr of Cos's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SGC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Superior Gr of Cos analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About Superior Gr of Cos</h2>
<p>Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.</p>
<h3>Superior Gr of Cos's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> Superior Gr of Cos's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-1.26%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Superior Gr of Cos's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-0.55%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Superior Gr of Cos's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-0.39%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-0.18%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.54</strong>, Superior Gr of Cos adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Assessing Superior Gr of Cos: Insights From 4 Financial Analysts

<p>Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Estee Lauder Cos, revealing an average target of $66.64, a high estimate of $90.00, and a low estimate of $55.00. Highlighting a 10.9% decrease, the current average has fallen from the previous average price target of $74.79. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748541709_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Estee Lauder Cos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$66.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$76.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$62.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$76.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Christopher Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$67.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Estee Lauder Cos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Estee Lauder Cos compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Estee Lauder Cos's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Estee Lauder Cos analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Estee Lauder Cos</h2>
<p>Estée Lauder is a leader in the global prestige beauty market, participating across skin care (51% of fiscal 2024 sales), makeup (29%), fragrance (16%), and hair care (4%) categories, with top-selling brands such as Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 30% of revenue from the Americas, 39% from Europe, the Middle East and Africa (including travel retail), and 31% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.</p>
<h3>Estee Lauder Cos: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Estee Lauder Cos faced challenges, resulting in a decline of approximately <strong>-9.9%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Estee Lauder Cos's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.48%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Estee Lauder Cos's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.74%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.8%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.16</strong>, caution is advised due to increased financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Estee Lauder Cos Stock

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

Shares of USlisted Chinese stocks led are trading higher after a federal court invalidated global tariffs enacted by President Donald Trump under the International Emergency Economic Powers Act on Wednesday.

<p>Throughout the last three months, 12 analysts have evaluated Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Rhythm Pharmaceuticals, presenting an average target of $76.58, a high estimate of $94.00, and a low estimate of $66.00. This current average reflects an increase of 8.13% from the previous average price target of $70.82. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748541700_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Rhythm Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Rhythm Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Rhythm Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Rhythm Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Get to Know Rhythm Pharmaceuticals Better</h2>
<p>Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.</p>
<h3>Financial Insights: Rhythm Pharmaceuticals</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Rhythm Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>25.94%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Rhythm Pharmaceuticals's net margin excels beyond industry benchmarks, reaching <strong>-155.39%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-249.88%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Rhythm Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-13.05%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.21</strong>, Rhythm Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RYTM

12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know

<p><strong>Dick's Sporting Goods Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) reported weaker-than-expected first-quarter 2025 <a href="https://www.benzinga.com/quote/DKS/earnings">results on Wednesday</a>.</p>
<p>The company reported first-quarter adjusted earnings per share of $3.37, missing the analyst consensus estimate of $4.34. Quarterly sales of $3.17 billion (+5.2% year over year) missed the Street view of $3.59 billion.</p>
<p>"Earlier this month, we announced our plans to acquire Foot Locker, a move that represents a truly exciting and transformational moment for Dick's. For many years we've admired Foot Locker's brand and the powerful community they've built in sneaker culture. By bringing our two great brands together, we see the opportunity to create a global leader in the sports retail industry by serving a broader set of athletes," said Ed Stack, executive chairman of Dick's Sporting Goods.</p>
<p>The company maintained its FY2025 sales forecast of $13.60 billion to $13.90 billion, compared with the analyst expectations of $13.86 billion.</p>
<p>It reaffirmed the FY2025 GAAP EPS outlook of $13.80 to $14.40, which includes the expected impact from all tariffs currently in effect.</p>
<p>Dick's shares gained 1.2% to trade at $179.24 on Thursday.</p>
<p>These analysts made changes to their price targets on Dick's following earnings announcement.</p>
<ul class="wp-block-list">
<li>DA Davidson analyst Michael Baker maintained Dick&#8217;s Sporting Goods with a Buy and lowered the price target from $273 to $230.</li>
<li>JP Morgan analyst Christopher Horvers maintained the stock with a Neutral and lowered the price target from $224 to $195.</li>
<li>Barclays analyst Adrienne Yih maintained the stock with an Overweight rating and raised the price target from $217 to $232.</li>
<li>UBS analyst Michael Lasser maintained Dick&#8217;s Sporting Goods with a Buy and lowered the price target from $260 to $225.</li>
</ul>
<p><strong>Considering buying DKS stock? Here&#8217;s what analysts think:</strong> </p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DKS/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="608" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29140026/image-396-1024x608.png" alt="" class="wp-image-932036" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29140026/image-396-1024x608.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29140026/image-396-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29140026/image-396-768x456.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29140026/image-396.png 1070w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read This Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/25/05/45667868/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a></strong> </li>
</ul>
<p>Photo via Shutterstock</p>


Earnings

Price Target

Markets

These Analysts Revise Their Forecasts On Dick's Sporting Goods After Q1 Results

<p>Monro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.8, a high estimate of $21.00, and a low estimate of $15.00. A 14.42% drop is evident in the current average compared to the previous average price target of $20.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748541685_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Monro is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Lantz</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Lantz</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Thomas Wendler</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Thomas Wendler</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Monro. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Monro compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Monro's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Monro's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MNRO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Monro analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Monro Better</h2>
<p>Monro Inc is a provider automobile service stations in the United States. Through its network of company-owned service stations, Monro Muffler Brake offers maintenance, repair, tire, and fleet management services for automobiles focused largely on undercar services such as brake, steering, exhaust, drivetrain, and suspension systems. Next to service stores, the company also offers tire stores specialised in tire replacement and service.</p>
<h3>Monro's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Monro's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-3.74%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Monro's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>1.39%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Monro's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>0.65%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.25%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Monro's debt-to-equity ratio is below the industry average at <strong>0.83</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MNRO

The Analyst Verdict: Monro In The Eyes Of 5 Experts

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Meta Platforms</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with META, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 73 uncommon options trades for Meta Platforms.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 35% bullish and 41%, bearish.</p>
<p>Out of all of the special options we uncovered, 18 are puts, for a total amount of $2,679,357, and 55 are calls, for a total amount of $4,778,604.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $900.0 for Meta Platforms over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Meta Platforms's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Meta Platforms's whale trades within a strike price range from $5.0 to $900.0 in the last 30 days. </p>
<h3>Meta Platforms Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748541683_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$119.8</td>
<td>$118.6</td>
<td>$118.9</td>
<td>$710.00</td>
<td>$1.7M</td>
<td>258</td>
<td>150</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$642.5</td>
<td>$639.55</td>
<td>$641.76</td>
<td>$5.00</td>
<td>$641.7K</td>
<td>6.9K</td>
<td>32</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$643.15</td>
<td>$639.1</td>
<td>$641.29</td>
<td>$5.00</td>
<td>$641.2K</td>
<td>6.9K</td>
<td>22</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$641.5</td>
<td>$638.35</td>
<td>$640.16</td>
<td>$5.00</td>
<td>$640.1K</td>
<td>5.1K</td>
<td>10</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$9.5</td>
<td>$9.45</td>
<td>$9.5</td>
<td>$640.00</td>
<td>$191.0K</td>
<td>2.9K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Meta Platforms</h3>
<p>Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.</p>
<h3>Current Position of Meta Platforms</h3>
<ul>
<li>With a volume of 5,577,122, the price of META is up 0.18% at $644.77. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 62 days.</li>
</ul>
<h3>Expert Opinions on Meta Platforms</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $721.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Meta Platforms, targeting a price of $675.<br />
&#x2A; Maintaining their stance, an analyst from TD Securities continues to hold a Buy rating for Meta Platforms, targeting a price of $700.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Meta Platforms with a target price of $655.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Meta Platforms, targeting a price of $690.<br />
&#x2A; An analyst from Loop Capital persists with their Buy rating on Meta Platforms, maintaining a target price of $888. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Meta Platforms with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Meta Platforms Unusual Options Activity

<p>Deep-pocketed investors have adopted a bullish approach towards Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BTDR usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Bitdeer Technologies. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $432,250, and 8 are calls, amounting to $414,993.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.5 to $16.0 for Bitdeer Technologies over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Bitdeer Technologies's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Bitdeer Technologies's substantial trades, within a strike price spectrum from $7.5 to $16.0 over the preceding 30 days.</p>
<h3>Bitdeer Technologies Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748541678_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BTDR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.05</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$14.00</td>
<td>$392.2K</td>
<td>3.9K</td>
<td>3.9K</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$0.4</td>
<td>$0.3</td>
<td>$0.4</td>
<td>$16.00</td>
<td>$65.8K</td>
<td>548</td>
<td>3.2K</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.9</td>
<td>$6.8</td>
<td>$6.8</td>
<td>$10.00</td>
<td>$54.4K</td>
<td>7.2K</td>
<td>497</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.8</td>
<td>$6.6</td>
<td>$6.8</td>
<td>$10.00</td>
<td>$54.4K</td>
<td>7.2K</td>
<td>80</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.8</td>
<td>$6.6</td>
<td>$6.8</td>
<td>$10.00</td>
<td>$50.9K</td>
<td>7.2K</td>
<td>205</td>
</tr>
</tbody>
</table>
</p>
<h3>About Bitdeer Technologies</h3>
<p>Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.</p>
<p>In light of the recent options history for Bitdeer Technologies, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Bitdeer Technologies Standing Right Now?</h3>
<ul>
<li>With a volume of 3,297,957, the price of BTDR is up 1.75% at $14.55. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 74 days.</li>
</ul>
<h3>What The Experts Say On Bitdeer Technologies</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $18.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Bitdeer Technologies with a target price of $17.<br />
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Bitdeer Technologies, maintaining a target price of $20.<br />
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on Bitdeer Technologies with a target price of $15.<br />
&#x2A; An analyst from B. Riley Securities has decided to maintain their Buy rating on Bitdeer Technologies, which currently sits at a price target of $18.<br />
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $24.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bitdeer Technologies options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


BTDR

Check Out What Whales Are Doing With BTDR

<p>Deep-pocketed investors have adopted a bullish approach towards PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PDD usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 26 extraordinary options activities for PDD Holdings. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 50% leaning bullish and 38% bearish. Among these notable options, 10 are puts, totaling $1,692,653, and 16 are calls, amounting to $894,408.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $140.0 for PDD Holdings over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of PDD Holdings stands at 3390.96, with a total volume reaching 10,045.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in PDD Holdings, situated within the strike price corridor from $80.0 to $140.0, throughout the last 30 days.</p>
<h3>PDD Holdings Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748541672_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$10.25</td>
<td>$9.9</td>
<td>$10.25</td>
<td>$95.00</td>
<td>$1.0M</td>
<td>6.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$41.4</td>
<td>$40.55</td>
<td>$41.0</td>
<td>$140.00</td>
<td>$204.9K</td>
<td>4.0K</td>
<td>100</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$7.1</td>
<td>$6.8</td>
<td>$7.0</td>
<td>$95.00</td>
<td>$158.9K</td>
<td>2.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$15.4</td>
<td>$15.3</td>
<td>$15.39</td>
<td>$110.00</td>
<td>$138.6K</td>
<td>248</td>
<td>102</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$21.85</td>
<td>$21.6</td>
<td>$21.85</td>
<td>$95.00</td>
<td>$131.1K</td>
<td>164</td>
<td>98</td>
</tr>
</tbody>
</table>
</p>
<h3>About PDD Holdings</h3>
<p>PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.</p>
<p>After a thorough review of the options trading surrounding PDD Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of PDD Holdings</h3>
<ul>
<li>Currently trading with a volume of 12,326,478, the PDD's price is up by 0.84%, now at $98.7. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>Expert Opinions on PDD Holdings</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $125.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Benchmark persists with their Buy rating on PDD Holdings, maintaining a target price of $128.<br />
&#x2A; In a positive move, an analyst from Citigroup has upgraded their rating to Buy and adjusted the price target to $165.<br />
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on PDD Holdings with a target price of $121.<br />
&#x2A; Reflecting concerns, an analyst from China Renaissance lowers its rating to Hold with a new price target of $107.<br />
&#x2A; An analyst from JP Morgan persists with their Neutral rating on PDD Holdings, maintaining a target price of $105. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for PDD Holdings, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


PDD Holdings Options Trading: A Deep Dive into Market Sentiment

<p>Throughout the last three months, 5 analysts have evaluated NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $41.9, a high estimate of $44.00, and a low estimate of $38.00. This current average has decreased by 6.47% from the previous average price target of $44.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748541673_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of NexPoint Residential among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Merrill Ross</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$42.50</td>
<td>$50.00</td>
</tr>
<tr>
<td>Buck Horne</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Linda Tsai</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$43.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$42.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NexPoint Residential. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NexPoint Residential compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into NexPoint Residential's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NXRT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on NexPoint Residential analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering NexPoint Residential: A Closer Look</h2>
<p>NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.</p>
<h3>NexPoint Residential's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, NexPoint Residential faced challenges, resulting in a decline of approximately <strong>-6.45%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-10.91%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> NexPoint Residential's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-1.75%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> NexPoint Residential's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.36%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>3.86</strong>, NexPoint Residential faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NXRT

What 5 Analyst Ratings Have To Say About NexPoint Residential

Press Releases

TMCI Investors Have Opportunity to Lead Treace Medical Concepts, Inc. Securities Fraud Lawsuit

Legal

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TMCI

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Treace Medical Concepts, Inc of Class Action Lawsuit and Upcoming Deadlines - TMCI

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

TREACE MEDICAL CONCEPTS, INC. (NASDAQ: TMCI) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Treace Medical Concepts, Inc. Investors of Upcoming Deadline

Deadline Alert: Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Small Cap

Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

TMCI DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action – TMCI

Comments

Treace Medical Concepts

空売り

Treace Medical Concepts (NASDAQ:TMCI) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル